NSE:MAXHEALTH 17 December 2025

April 29, 2026, 4:11 AM EDT. Pfizer's (PFE) stock recently dropped 3% over a week and 2.1% over 30 days, closing at $26.48. Despite short-term weakness, the one-year return still stands at 19.4%, outperforming broader declines over 3 and 5 years. A discounted cash flow (DCF) analysis estimates Pfizer's intrinsic value at $64.92 per share, signaling a 59.2% undervaluation compared to its current price. The company's value score is moderate, reflecting mixed signals on undervaluation. Investors consider factors like regulatory pressures, drug pipelines, and sector competition in their evaluations. With a recent free cash flow of $8.5 billion and projected growth to $16.4 billion by 2030, Pfizer's long-term prospects appear solid. The price-to-earnings (P/E) ratio also plays a key role in assessing market expectations against current earnings.